Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility

On Jan 11, 2021

Cranbury-based Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces plans for the buildout of a new Research and Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operation, which will also serve as the company’s new headquarters. The new 103,720-square-foot facility will support clinical development of Rocket’s growing pipeline of lentivirus (LV) and adeno-associated virus (AAV) gene therapies from discovery through pivotal trials, with space for potential future expansion and commercialization.

This buildout comes on the heels of the company’s recent successful capital raise of approximately $300 million that provides a cash runway into the second half of 2023.

“Investing in R&D and manufacturing innovation, talent, and capacity through this new world-class facility will allow us to deliver on our mission of bringing five curative gene therapies to rare disease patients by 2025,” said Gaurav Shah, M.D., president and chief executive officer of Rocket. “With data on five clinical programs expected this year, including two that are in registration-enabling trials, these new capabilities will enable us to work with continued urgency and purpose towards bringing transformational therapies to patients.”

“We are collaborating with some of the best scientists and innovators worldwide. This new facility is instrumental in bolstering Rocket’s gene therapy capabilities to rapidly advance multiple platforms and programs efficiently and effectively. Producing clinical drug product will enable greater control of supply, cost, quality, and timing to pave a smoother path toward commercialization,” added Kinnari Patel, Pharm.D., MBA, chief operating officer and head of development.

Approximately one-half of the facility is being scaled for AAV Current Good Manufacturing Practice (cGMP) production. The other half features state-of-the-art R&D labs to support the expanding pipeline and Quality Control (QC) laboratories to support CMC development for process and analytics.

To access more business news, visit NJB News Now.

Related Articles: